Short-term and long-term outcomes of induction chemoimmunotherapy before radical thoracic radiotherapy or chemoradiotherapy for unresectable stage III non-small cell lung cancer
Abstract:Background Consolidation therapy of durvalumab after concurrent chemoradiotherapy (cCRT) has been the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). In this retrospective study, we assessed the safety and efficacy of induction chemoimmunotherapy in unresectable stage III NSCLC.Materials and method unresectable stage III NSCLC who received at least one cycle of induction chemoimmunotherapy and underwent radical thoracic radiotherapy (RT) were retrospectively collected. The impa… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.